Related Experiment Video

Updated: Jun 14, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an

Bram De Laere1,2, Alessio Crippa1, Andrea Discacciati1

  • 1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Nature Medicine
|August 28, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Experiment Videos

Last Updated: Jun 14, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

Articles linked to this work by shared authors, journal, and citation graph.

Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Cyclosporine treatment of ARDS due to severe COVID-19: The I-SPY COVID Adaptive Platform Trial.

Annals of the American Thoracic Society·2026

Lower proportion of bladder cancer diagnosed at unscheduled hospitalization after introduction of standardized care pathways in Sweden.

Scandinavian journal of urology·2026

Estimation of glomerular filtration rate by standard renal CT imaging.

Insights into imaging·2026

Artificial Intelligence for Prostate Cancer Detection and Screening on MRI in Global Populations: The SCARLET-1 Study.

Radiology·2026

Fracture risk and initiation of bone-specific drug therapy following radical cystectomy with urinary diversion.

BJU international·2026

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.

Nature medicine·2026

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.

Nature medicine·2026

Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial.

Nature medicine·2026

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial.

Nature medicine·2026

Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma.

Nature medicine·2026

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.

Nature medicine·2026

SOX2/TSTA3 suppresses CD8+ T-cell-mediated immune response in breast cancer by regulating programmed death ligand-1 fucosylation.

Journal of leukocyte biology·2026

CLDN18.2 ADCs "A Real Step Forward" for Stomach Cancer.

Cancer discovery·2026

Gene Therapy for Osteoarthritis: Viral and Non-Viral Delivery Strategies.

Viruses·2026

Inactivated SARS-CoV-2 Exposure Induces Inflammation and Impairs Reproductive Outcomes in Mice.

Viruses·2026

Systems-Level Decoding of Redox Homeostasis in Cancer: From ROS Biology to Therapeutic Vulnerabilities.

Molecules (Basel, Switzerland)·2026

Silymarin Attenuates Nicotine-Associated Testicular Degeneration and Systemic Oxidative and Inflammatory Changes in Mice.

Molecules (Basel, Switzerland)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us